Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viekira Pak or Mavyret in HCV with Advanced CKD
NCT02946034Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2017
- Primary completion
- Sep 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of Viekira Pak, glecaprevir in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Started Feb 2017; status: completed.
02
Drugs
Viekira Pakglecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02946034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946034.